Simponi® | Golimumab | Janssen

August 11, 2020

11 Aug 2020 | All | Janssen | Docwirenews reports a new post-approval safety surveillance study of Janssen's golimumab Simponi® demonstrated that there is no association between exposure to golimumab and an increased risk of prespecified outcomes.


17 Jul 2020 | RU | Bio-Thera, Pharmapark | Bio-Thera Solutions annnounces a licensing agreement with Pharmapark for BAT2506 (biosimilar golimumab candidate). Under the agreement, Pharmapark will have exclusive rights to distribute and market the drug in Russia and other CIS countries.


22 Jun 2020 | All | Janssen | Ankylosing Spondylitis News reports new data from Germany indicates Simponi® (golimumab) is an effective therapy for people with ankylosing spondylitis and other chronic inflammatory conditions, regardless of pre-treatment with other TNF inhibitors.


24 Apr 2020 | US | Johnson & Johnson | J&J announces it has filed two supplemental marketing applications for Simponi Aria (golimumab) with the FDA. J&J have applied for the additional indications of polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in patients at least two years old.


14 Aug 2019 | All | Bio-Thera Solutions |  Bio-Thera announces commencement of Ph I trials of proposed golimumab biosimilar. 







Share on Facebook
Share on Twitter
Please reload

Biosimilars Bulletin 

August 19, 2020

Please reload

Search by tags